Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

Shownotes

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.

Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.

They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.

Read the full article:

thelancet.com/journals/lanonc/article/PIIS1470…)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanonc (thelancet.com/journals/lanonc/article/PIIS1470…)00358-4/abstract?rss=yes?dgcid=buzzsprout_icw_podcast_September_25_lanonc)

Tell us what you thought about this episode (buzzsprout.com/1391338/fan_mail/new)

Continue this conversation on social!

thelancet.bsky.social

instagram.com/thelancetgroup

facebook.com/thelancetmedicaljournal

linkedIn.com/company/the-lancet (linkedin.com/company/the-lancet)

youtube.com/thelancettv